Tag Archives: Glivec

Does India's Glivec Decision Make April Fools of Us All?

By Helen Disney, Pugatch Consilium. On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual […]
Posted in Global, Guest Blog, IP, Legal, Op-Ed | Also tagged , , | 2 Comments

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, pricing, Strategy | Also tagged , , , , , , , | 6 Comments
  • Categories

  • Meta